Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | TACR1 | P25103 | 4/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
| ▸ | AURKA | O14965 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6902335 | 0.81 | TACR1 (0.38) | ALDH1A1HPGDHTTTACR1NOTUM | |
| SCHEMBL6920360 | 0.81 | TACR1 (0.36) | TACR1 | |
| SCHEMBL6899145 | 0.80 | GABRP (0.37) | ALDH1A1HPGDHTTTACR1NOTUM | |
| SCHEMBL6906733 | 0.79 | MEN1 (0.30) | TACR1 | |
| SCHEMBL8326702 | 0.76 | TACR1 (0.38) | ALDH1A1HPGDHTTTACR1 | |
| SCHEMBL8658515 | 0.74 | MYC (0.40) | ALDH1A1TACR1 | |
| SCHEMBL6906060 | 0.73 | ALDH1A1 (0.39) | ALDH1A1TACR1 | |
| SCHEMBL6918745 | 0.69 | HSD17B10 (0.35) | TACR1 | |
| SCHEMBL1973007 | 0.68 | ALDH1A1 (0.61) | ALDH1A1HPGDHTTTACR1 | |
| SCHEMBL6900107 | 0.67 | CYP1A2 (0.37) | HTTAURKAKDRAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040220403-A1 | 1-(2-Methoxybenzyl)-3-benzhydrylpiperazines as tachykinin anatgonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220403-A1 | 1-(2-Methoxybenzyl)-3-benzhydrylpiperazines as tachykinin anatgonists | BDKRB1, BDKRB2, TACR1 | ALDH1A1 1825/4885HPGD 1665/4885HTT 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.